Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Advanced Esophageal Cancer.

Ningning Cheng,Yong Liu,Guoqi Zhao,Yi Xu,Tiening Zhang, Ying Chen,Ge Yan,Ye Hu,Shengyu Yao, Zijie Wang,Chungang Wang,Zhixiao Chen,Zhekai Hu,Dongli Liu,Tingfeng Chen

International Journal of Radiation Oncology*Biology*Physics（2020）

引用 2|浏览43

暂无评分

摘要

The MTD of the HFRT boost following standard chemoradiotherapy in the setting of concurrent chemotherapy was 36 Gy, resulting in the cumulative tumor dose of 86 Gy in patients primarily with advanced intra-thoracic/cervical esophageal squamous cell carcinomas and not adenocarcinomas of the gastroesophageal junction. A phase II study to further evaluate this regimen is underway.

查看译文

关键词

standard chemoradiotherapy,radiotherapy,concurrent chemotherapy,squamous cell carcinomas,intensity-modulated,intra-thoracic

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要